NovoCure

NVCR Small Cap

Healthcare · Medical Devices

Updated: Apr 5, 2026, 17:43 UTC

$10.55

-2.68% today

52W: $9.82 – $20.06

52W Low: $9.82 Position: 7.1% 52W High: $20.06

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

1.83x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$1.2B

Market Capitalization

Revenue Growth

8.1%

YoY Revenue Growth

Profit Margin

-20.79%

Net profit margin

ROE

-38.89%

Return on Equity

Beta

0.82

Market sensitivity

Short Interest

11.71%

% of float sold short

Avg. Volume

1,912,900

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

7 analysts

Avg. Price Target

$26.07

+147.12% upside

Target Range

$13.50 – $49.00

About the Company

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Sector: Healthcare Industry: Medical Devices Country: Switzerland Employees: 1,605 Exchange: NMS